Welcome to our dedicated page for Calumet SEC filings (Ticker: CLMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for Calumet, Inc. (NASDAQ: CLMT), a petroleum refineries industry company that manufactures, formulates and markets specialty branded products and renewable fuels. Through these filings, investors can review Calumet’s regulatory disclosures on operations, financing activities, internal controls and segment performance across Specialty Products and Solutions, Montana/Renewables, Performance Brands and Corporate.
Current reports on Form 8-K are a central source of Calumet information. The company uses Item 2.02 filings to furnish results of operations and financial condition for specific quarters, referencing press releases that contain detailed financial data. These 8-Ks allow readers to see how Calumet reports quarterly performance, including metrics such as net income (loss) and non-GAAP measures like Adjusted EBITDA and Adjusted EBITDA with Tax Attributes, which the company explains in its disclosures.
Calumet has also filed 8-Ks under Item 4.02 describing non-reliance on previously issued financial statements. In one such filing, the Audit Committee concluded that unaudited interim consolidated financial statements for certain 2025 periods required restatement due to an error in the unaudited condensed consolidated statements of cash flows. The company explained that the error involved misclassification between operating and financing cash flows, did not affect revenue, net income (loss) or cash and cash equivalents, and was associated with a material weakness in internal control over financial reporting. The filing outlines planned restatements and discussions with the independent registered public accounting firm.
Other 8-K filings detail material definitive agreements and related transactions. For example, Calumet reported a sale and leaseback transaction for property comprising the Shreveport refinery fuels terminal, truck rack and related piping and equipment, documented under a Master Lease Agreement and property schedule with Stonebriar Commercial Finance LLC. The filing describes lease terms, rental payments, an option to repurchase the leased assets, application of proceeds to prior obligations, and related amendments to the company’s credit agreement and monetization master agreement.
Calumet’s filings also reference its capital structure, including various series of senior notes such as 11.00% Senior Notes due 2026, 8.125% Senior Notes due 2027, 9.75% Senior Notes due 2028 (including a mirror issuance), and 9.25% Senior Secured First Lien Notes due 2029. Definitions of "Consolidated Cash Flow" and "Consolidated EBITDA" used in these instruments are linked to the company’s non-GAAP measures, and the filings explain how these metrics are reported to noteholders and lenders.
On Stock Titan, Calumet’s SEC filings are updated from EDGAR and presented with AI-powered summaries. AI analysis highlights key terms in 10-K and 10-Q reports, explains complex sections such as non-GAAP reconciliations and covenant definitions, and surfaces important items from 8-Ks, including restatement notices, internal control disclosures and material transactions. Users can also review Form 4 and other ownership filings to track insider transactions, alongside proxy and other statements that address governance and compensation when available.
By combining real-time access to Calumet’s SEC submissions with AI-generated explanations, this page helps readers understand how the company reports its specialty products and renewable fuels operations, manages its capital structure and addresses financial reporting and control matters in its official filings.
Calumet, Inc. (CLMT) disclosed a Form 4 showing a director received two Restricted Stock Unit awards on 11/06/2025. The filings list 1,761 RSUs (100% vested, to be settled upon the earlier of a specified date or termination) and 587 RSUs (under the Deferred Compensation Plan, vesting 25% each July 1 beginning July 1, 2026). Both derivative positions are shown as Direct (D) ownership at a price of $0 per unit.
Calumet, Inc. (CLMT) reported a routine insider equity event. A director filed a Form 4 showing two grants of restricted stock units on 11/06/2025: 1,172 RSUs and 390 RSUs, each acquired at $0 and held directly. Each RSU represents the economic equivalent of one share of Calumet common stock.
The filing notes distinct settlement and vesting terms. The 1,172 RSUs are 100% vested and settle upon the earlier of a date specified by the reporting person or their termination date. The 390 RSUs, granted under a Deferred Compensation Plan, settle on the same trigger, with 25% vesting on July 1 of each year beginning July 1, 2026.
Calumet, Inc. reported a strong turnaround in Q3 2025. Sales were $1,078.0 million and gross profit jumped to $373.7 million. Operating income reached $322.9 million, and net income was $313.4 million (basic and diluted EPS $3.61), compared with a loss a year ago. For the first nine months, sales were $3,098.5 million and net income was $3.5 million.
Cash and cash equivalents were $94.6 million, with $80.0 million of restricted cash. Total assets were $2,733.9 million and total liabilities were $3,183.6 million, leaving stockholders’ equity at $(695.3) million. The RINs obligation stood at $133.0 million, down from $245.4 million at year-end.
Calumet closed the sale of assets related to the industrial portion of its Royal Purple business, receiving $95.4 million in cash and recording a $55.8 million gain. Financing cash flows included $781.8 million of proceeds from a DOE Loan. As of November 10, 2025, 86,754,321 common shares were outstanding.
Calumet, Inc. filed a Form 10‑Q/A to restate its unaudited Q2 2025 financials after identifying a cash flow classification error between operating and financing activities. The company states the restatement had no impact on revenue, net income (loss), or cash, cash equivalents and restricted cash.
For Q1 2025 and H1 2025, operating cash flows were increased by approximately $81.3 million and $76.9 million, respectively, with equal reductions to financing cash flows. The restated amounts show $29.3 million and $31.1 million of net cash used in operating activities and $109.0 million and $111.6 million of net cash provided by financing activities for the three months ended March 31, 2025 and the six months ended June 30, 2025, respectively.
Management concluded a material weakness in internal control over financial reporting related to preparing and reviewing statements of cash flows, and determined disclosure controls and procedures as of June 30, 2025 were ineffective. Q2 2025 results include a net loss of $147.9 million and H1 2025 a net loss of $309.9 million. As of June 30, 2025, the recorded RINs Obligation was $457.0 million.
Calumet, Inc. (CLMT) filed a Form 10‑Q/A to restate Q1 2025 cash flows after identifying a misclassification between operating and financing activities. The correction, which had no impact on revenue, net income (loss) or cash, reclassifies debt extinguishment and inventory financing items.
The company revised operating cash flows for the three months ended March 31, 2025 by +$81.3 million, changing net cash used in operating activities to $29.3 million, and reduced financing cash flows by the same amount to $109.0 million. For the six months ended June 30, 2025, the reclassifications total +$76.9 million to operating and an equivalent decrease to financing. Management concluded a material weakness in internal control over financial reporting existed as of March 31, 2025, rendering disclosure controls ineffective.
Q1 also reflects a $62.2 million gain on the sale of the industrial portion of the Royal Purple business, with $95.4 million cash proceeds used to reduce indebtedness. The RINs obligation was $362.6 million as of March 31, 2025. The company will file a Q2 2025 10‑Q/A for the same classification issue and advises relying only on the amended quarters.
Calumet, Inc. (CLMT) furnished quarterly results under Item 2.02. On November 7, 2025, the company reported results for the quarter ended September 30, 2025 via a press release, which is included as Exhibit 99.1.
Consistent with General Instruction B.2, the information is furnished, not filed, and is not subject to Section 18 liabilities. It will not be incorporated by reference into other filings unless expressly stated.
Calumet, Inc. (CLMT) announced non‑reliance on its unaudited interim financial statements for the periods ended March 31, 2025 and June 30, 2025, due to a cash flow classification error in the statements of cash flows. The company will restate those periods and file amended Quarterly Reports on Form 10‑Q.
The error misclassified amounts between operating and financing cash flows and had no impact on revenue, net income (loss), or cash and cash equivalents. For the three months ended March 31, 2025, operating cash flow is expected to improve by approximately $81.3 million to $29.3 million of net cash used, with financing cash flow reduced to $109.0 million provided. For the six months ended June 30, 2025, operating cash flow is expected to improve by approximately $76.9 million to $31.1 million of net cash used, with financing cash flow reduced to $111.6 million provided.
Management and the Audit Committee identified a material weakness in internal control over financial reporting related to cash flow statement preparation and review, and concluded disclosure controls and procedures for those periods were ineffective.
Calumet, Inc. (CLMT) reported an insider equity change by a director. On June 24, 2025, the director converted 3,796 Restricted Stock Units (RSUs) into an equal number of shares of common stock, shown as transaction code M. The shares were acquired at $0 per share, reflecting a standard RSU settlement rather than a market purchase.
Following the transaction, the director beneficially owns 3,796 shares directly. The filing indicates the RSUs were 100% vested and payable in either shares or cash; the settlement here delivered common stock. No sales were reported, and the derivative RSU balance is now 0.
Amy M. Schumacher, a director of Calumet, Inc. (CLMT), reported receipt of 3,796 restricted stock units on 06/24/2025. The RSUs are described as the economic equivalent of one share each and are 100% vested. Each RSU is payable either in one share of Calumet common stock or the cash value thereof, and the reported acquisition price is $0 (reflecting issuance/settlement of RSUs rather than a cash purchase). The report lists 246,040 shares as the amount of securities beneficially owned following the transaction. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 10/03/2025.
Raymond Paul C, a director of Calumet, Inc. (CLMT), acquired 3,796 restricted stock units on 06/24/2025. The filing shows the RSUs were granted at $0 and are 100% vested, each convertible into one share of common stock or paid in cash. After the reported transaction, the reporting person beneficially owns 19,680 shares of Calumet common stock. The Form 4 was signed by an attorney-in-fact on 10/03/2025. The disclosure is a standard Section 16 statement documenting an insider grant and resulting ownership level.